The wet AMD program for DURAVYU in wet AMD is now at risk of discontinuation after two failed Phase 3 trials. The remaining pipeline value is entirely dependent on the DME program (COMO and CAPRI) topline data in Q4 2027. Monitor the conference call today for management's assessment of next steps for wet AMD and any potential regulatory path forward.
Price Chart
Executive Summary
EyePoint announced that LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, failed to meet its primary endpoint of statistical non-inferiority in mean change in BCVA versus aflibercept (DURAVYU +2.5 letters vs aflibercept +6.1 letters, difference -3.7 letters). Key secondary endpoints were met, including a 38% reduction in treatment burden (nominal p<0.0001) and 52% supplement-free rate at Week 56, with a favorable safety profile. The DME program (COMO and CAPRI trials) remains on track with topline data expected in Q4 2027.
Key Facts
- LUCIA did not achieve primary endpoint of non-inferiority in mean BCVA change vs aflibercept (DURAVYU +2.5 letters, aflibercept +6.1 letters, difference -3.7 letters, CI outside 4.5-letter margin)
- Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001), 52% supplement-free at Week 56, strong anatomic control
- LUGANO, the first Phase 3 wet AMD trial, also did not meet the primary endpoint in its full dataset
- DME program (COMO and CAPRI) remains on track with topline data expected in Q4 2027
- Favorable safety profile with redosing; no drug-related safety database covers over 630 patients across six completed trials
- LUCIA enrolled 475 patients; LUGANO enrolled 432 patients
Financial Impact
Two pivotal Phase 3 wet AMD trials (LUCIA and LUCIA) both failed to meet primary endpoint in wet AMD, effectively ending the wet AMD regulatory pathway for DURAVYU in that indication; DURAVYU's wet AMD program is now at risk of discontinuation; DME program (DME) is the remaining pipeline value driver with topline data in Q4 2027
Risk Factors
- DURAVYU wet AMD program may be discontinued after two failed Phase 3 trials; DME program is the remaining pipeline value driver with topline data in Q4 2027; potential need for additional financing if wet AMD program is discontinued
- relatedTickers: [
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424644 |
| Document: eypt-ex99_1.htm | 0001193125-26-424644 |
| Document: eypt-ex99_2.htm | 0001193125-26-424644 |
| Document: 0001193125-26-424644-index-headers.html | 0001193125-26-424644 |
| Document: 0001193125-26-424644-index.html | 0001193125-26-424644 |
| Document: 0001193125-26-424644.txt | 0001193125-26-424644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 19d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3700 (−97.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers